The trend: AI is advancing further into pharmaceutical commercialization and marketing as brand naming agencies build proprietary platforms to create distinctive and compliant names for new prescription drugs.

New platforms debuted last year, including Brand Institute’s Brandi, Addison Whitney’s Ari, and Brandsymbol’s MOSAIC. They are using AI as a creative co-pilot, rapidly producing viable name candidates that human teams curate, refine, and develop.

Why it matters: In the US, a drug’s name is central to its marketing strategy, influencing brand positioning and helping build trust and positive perceptions with both consumers and physicians.

• 60% of Americans prefer to buy brand-name drugs, but get generics instead because of the cost, according to a Tebra report in January.
• 62% of those who prefer brand-name drugs say they trust them more, compared to 13% who trust generics more.
• 57% say they choose brand-name drugs for the perception of quality, per Tebra.

Implications for pharma marketers: As AI enters the drug-naming process, it is changing the workflow, expectations, and strategic considerations for pharma marketers.

Here's how AI is poised to reshape drug naming:

• Accelerates launch timelines. AI rapidly generates and vets large volumes of names, shrinking early-stage branding cycles.
• Expands creative possibilities in a highly constrained space. Since drug names cannot imply attributes or promise benefits, AI navigates global regulations to generate compliant, health-positive options, resulting in greater strategic nuance and fewer compliance dead ends.
• Strengthens regulatory readiness. AI improves pre-screening for look-alike/sound-alike risks and cross-market compliance, reducing costly rejections.
• Boosts strategic positioning in one of pharma’s key brand assets. Drug names are often criticized for being long or hard to pronounce, but landing on a strong one—like Keytruda or Skyrizi —can meaningfully enhance differentiation and strengthen the brand story.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.